𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration

✍ Scribed by J. Dubois; G. Atassi; M. Hanocq; F. Abikhalil


Publisher
Springer
Year
1986
Tongue
English
Weight
484 KB
Volume
18
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

✦ Synopsis


The pharmacokinetics of hexamethylmelamine (HMM) and its first metabolite (hydroxymethylpentamethylmelamine: HMPMM) following IP bolus dose of 200 mg/kg were studied in mice. The drug concentrations were determined by a sensitive reversed-phase HPLC assay. Thus, for the first time, HMM major hydroxylated and demethylated metabolite plasma levels canbedetermined at the same time. Pharmacokinetic data were analyzed by an original method using a nonlinear cost function minimized by a simplex algorithm. An important property of this computer program is that convergence is ensured in contrast to linear or nonlinear least-square regression analysis, which leads to lack of convergence or to false convergence. Both HMM and HMPMM data fit a one-compartment open model. The parameters obtained indicate that the parent drug would probably be rapidly and completely transformed by the human body into HMPMM.


πŸ“œ SIMILAR VOLUMES


Pharmacokinetics and metabolism of hexam
✍ J. Dubois; G. Atassi; M. Hanocq; F. Abikhalil πŸ“‚ Article πŸ“… 1988 πŸ› Springer 🌐 English βš– 593 KB

The pharmacokinetics of hexamethylmelamine (HMM) and its main metabolites hydroxymethylpentamethylmelamine (HMPMM), pentamethylmelamine (PMM), and 2,2,4,6, tetramethylmelamine (2,2,4,6 TetrMM) were studied in renal cell (RC) tumor tissues and plasma of CDF1 mice that had received IP bolus injections

Integrated pharmacokinetic and metabolic
✍ Shashank Rohatagi; Jeffrey S. Barrett; Kimberly E. Dewitt; Richard J. Morales πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 249 KB πŸ‘ 2 views

Selegiline (SEL) is a selective, irreversible inhibitor of MAO-B, used in the treatment of Parkinson's disease, either alone or as an adjunct to L-DOPA. Selegiline hydrochloride (HCl) undergoes significant first-pass metabolism following oral administration. Transdermal delivery avoids the first-pas